Search

Your search keyword '"A. Armuzzi"' showing total 3,707 results

Search Constraints

Start Over You searched for: Author "A. Armuzzi" Remove constraint Author: "A. Armuzzi"
3,707 results on '"A. Armuzzi"'

Search Results

1. The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease

2. Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis

3. The evolution of IBD perceived engagement and care needs across the life-cycle: a scoping review

4. Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report

6. High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis

7. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

8. Optimising surgical anastomosis in ileocolic resection for Crohn’s disease with respect to recurrence and functionality: two international parallel randomized controlled trials comparing handsewn (END-to-end or Kono-S) to stapled anastomosis (HAND2END and the End2End STUDIES)

9. Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features

10. Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

12. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

13. Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

15. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

16. A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

18. Transition care in patients with IBD: The pediatric and the adult gastroenterologist's perspective. Results from a national survey

19. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

24. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

26. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management

30. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves

34. Radiomics could predict surgery at 10 years in Crohn's disease

36. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology

39. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

40. Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn′s Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition

43. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

45. Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach.

46. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

48. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results

49. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results

50. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Catalog

Books, media, physical & digital resources